Time-dependent predictors of loss to follow-up in a large HIV treatment cohort in Nigeria

Open Forum Infectious Diseases

Volumn 1, Issue 2, 2014, Pages

  Meloni, Seema Thakore ^a   Chang, Charlotte ^a   Chaplin, Beth ^a   Rawizza, Holly ^a,b   Jolayemi, Oluwatoyin ^c   Banigbe, Bolanle ^c   Okonkwo, Prosper ^c   Kanki, Phyllis ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c APIN PUBLIC HEALTH INITIATIVES   (Nigeria)

Author keywords

ART outcomes; Attrition; HIV; Loss to follow up; Retention

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOSS TO FOLLOW UP; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NIGERIA; OCCUPATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; VIRUS LOAD;

EID: 84929682098     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu055     Document Type: Article

References (40)

1. Federal Ministry of Health Nigeria. 2010 National HIV sero-prevalence sentinel survey. Abuja, Nigeria, 2010.
2. Federal Republic of Nigeria National Agency for the Control of AIDS. Global AIDS response: Country progress report. Nigeria, 2012.
3. World Bank. Nigeria: Country at a glance.Washington, DC The World Bank, 2012.
4. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4 (10):e298.
5. Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2008;47 (1):101-107.
6. Ahonkhai AA, Noubary F, Munro A, et al. Not all are lost: Interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. PLoS One. 2012;7(3):e32993.
7. Somi G, Keogh SC, Todd J, et al. Low mortality risk but high loss to follow-up among patients in the Tanzanian national HIV care and treatment programme. Trop Med Int Health. 2012;17(4): 497-506.
8. Zhou J, Tanuma J, Chaiwarith R, et al. Loss to follow-up in HIV-infected patients from Asia-Pacific Region: Results from TAHOD. AIDS Res Treat. 2012;2012:375217.
9. Alvarez-Uria G, Naik PK, Pakam R, et al. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: Data from an HIV cohort study in India. Glob Health Action. 2013;6:21682.
10. Clouse K, Pettifor AE, Maskew M, et al. Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e39-e46.
11. Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12(5):687-694.
12. BrinkhofMW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86(7):559-567.
13. Geng EH, Glidden DV, Emenyonu N, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health. 2010;15(Suppl 1):63-69.
14. Krishnan S, Wu K, Smurzynski M, et al. Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral- treated HIV-infected persons: An AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials. 2011;12(4):190-200.
15. Mosoko JJ, Akam W, Weidle PJ, et al. Retention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon. J Int AIDS Soc. 2011;14:32.
16. Wang B, Losina E, Stark R, et al. Loss to follow-up in a community clinic in South Africa-roles of gender, pregnancy and CD4 count. S Afr Med J. 2011;101(4):253-257.
17. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010;5(5): e10584.
18. Odafe S, Torpey K, Khamofu H, et al. The pattern of attrition from an antiretroviral treatment program in Nigeria. PLoS One. 2012;7(12): e51254.
19. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2006 rev. Geneva: World Health Organization, 2006.
20. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach-2010 rev. Geneva: WHO, 2010.
21. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57(10):1107-1110.
22. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84.
23. Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187-191.
24. Seguy N, Diaz T, Campos DP, et al. Evaluation of the consistency of refills for antiretroviral medications in two hospitals in the state of Rio de Janeiro, Brazil. AIDS Care. 2007;19(5):617-625.
25. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5(5):e109.
26. El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3):e17518.
27. Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88(9):681-688.
28. Ekouevi DK, Balestre E, Ba-Gomis FO, et al. Low retention of HIVinfected patients on antiretroviral therapy in 11 clinical centres in West Africa. Trop Med Int Health. 2010;15(Suppl 1):34-42.
29. Rasschaert F, Koole O, Zachariah R, et al. Short and long term retention in antiretroviral care in health facilities in rural Malawi and Zimbabwe. BMC Health Serv Res. 2012;12:444.
30. Maru DS, Khakha DC, Tahir M, et al. Poor follow-up rates at a self-pay northern Indian tertiary AIDS clinic. Int J Equity Health. 2007;6:14.
31. Cicconi P, Cozzi-Lepri A, Castagna A, et al. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naive patients. HIV Med. 2010;11(2):104-113.
32. Mocroft A, Kirk O, Aldins P, et al. Loss to follow-up in an international, multicentre observational study. HIV Med. 2008;9(5):261-269.
33. Bekolo CE,Webster J, Batenganya M, et al. Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional hospital, Cameroon. BMC Res Notes. 2013;6(1):512.
34. Guy R, Wand H, McManus H, et al. Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy. AIDS Patient Care STDS. 2013;27(12):681-691.
35. Honge BL, Jespersen S, Nordentoft PB, et al. Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: A 7-year retrospective cohort study. BMJ Open. 2013;3(10):e003499.
36. Rich ML, Miller AC, Niyigena P, et al. Excellent clinical outcomes and high retention in care among adults in a community-based HIV treatment program in rural Rwanda. J Acquir Immune Defic Syndr. 2012;59 (3):e35-e42.
37. Mutasa-Apollo T, Shiraishi RW, Takarinda KC, et al. Patient retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zimbabwe's national antiretroviral therapy programme, 2007-2010. PLoS One. 2014;9(1):e86305.
38. Geng EH, Emenyonu N, Bwana MB, et al. Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300(5):506-507.
39. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53(3):405-411.
40. Tuller DM, Bangsberg DR, Senkungu J, et al. Transportation costs impede sustained adherence and access to HAART in a clinic population in southwestern Uganda: A qualitative study. AIDS Behav. 2010;14 (4):778-784.